Answers are grounded in this paper and cite their sources.
Background: Tibremciclib (BPI-16350; TIB), a novel highly potent CDK4/6 inhibitor, improved progression-free survival (PFS) when combined with fulvestrant (FUL) versus placebo (PBO) plus FUL in patients with HR+/HER2- advanced breast cancer (ABC) that progressed on prior endocrine therapy in an interim analysis of a randomized, double-blind, phase III study (NCT05433480). Here, we report the updated analysis from the phase III study. Methods: Patients with post-menopausal status (natural or artificial) who had recurred during or within 12 months from the end of neo-adjuvant or adjuvant endocrine therapy or who progressed on the first-line endocrine therapy for metastatic disease were randomly assigned to receive TIB (400 mg orally once daily) or matching PBO plus FUL (500 mg intramuscularly on days 1 and 15 of 28 days of cycle 1, then day 1 of every subsequent cycle), in a 2:1 ratio between patients with TIB and PBO. The primary endpoint was investigator (INV)-assessed PFS, and key secondary endpoints were independent review committee (IRC)-assessed PFS, INV-assessed objective response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR); overall survival (OS) and safety. Results: A total of 274 patients were randomly assigned to receive TIB plus FUL (N = 184) or PBO plus FUL (N = 90). By the data cutoff date of March 31, 2024, the median follow-up was 12.88 months for either group. The median INV-assessed PFS was significantly longer with TIB plus FUL versus PBO plus FUL (16.53 months [95% CI 12.85-16.59] versus 5.59 months [95% CI 4.53-9.20], HR 0.37 [95% CI 0.27-0.52]; p<0.0001). Improvement in PFS was confirmed by the IRC analysis, with an HR of 0.37 (95% CI 0.26-0.54; p<0.0001). The INV-assessed confirmed ORR was 39.1% versus 10.0% (p<0.0001), DCR was 89.1% versus 76.7% (p=0.0053), and CBR was 74.5% versus 42.2% (p<0.0001) in the TIB group and PBO group, respectively. Median OS for the study has still not been reached (19.7% OS data maturity). Safety profiles showed no new safety signals from the interim analysis. The most common treatment-emergent adverse events (TEAEs) in the TIB group were diarrhea (79.3%; versus 13.3% for the PBO group), neutropenia (75.5%; versus 15.6%), and leukopenia (73.9%; versus 16.7%). The most common grade 3 or higher TEAE was neutropenia in the both groups (15.2% versus 5.6% for the TIB group and PBO group). The incidence for grade 3 or higher diarrhea was 4.9% in the TIB group and 1.1% in the PBO group. Serious adverse events (SAEs) occurred in 24 patients (13.0%) in the TIB group and 9 patients (10.0%) in the PBO group. TEAEs leading to dose discontinuation occurred in 4 patients (2.2%) for the TIB group and none for the PBO group. No treatment-related death in the TIB group and 1 death (1.1%) in the PBO group. Conclusions: Tibremciclib plus fulvestrant continued to demonstrate a statistically significant and clinically meaningful improvement in PFS for patients with HR+/HER2- ABC who had progressed on endocrine therapy. Safety prolife was aligned with the previous interim analysis, with no new safety findings identified. Citation Format: Zhonghua Tao, Jian Zhang, Qiufan Zheng, Yongsheng Wang, Li Cai, Hongyan Xu, Xinhua Xu, Xiangshun Kong, Sijuan Ding, Chunfang Hao, Hao Wang, Hong Zong, Xin Jin, Xinshuai Wang, Yang Li, Xiuli Yang, Peiqi Li, Lieming Ding, Shusen Wang, Xichun Hu. Tibremciclib (BPI-16350) plus fulvestrant versus placebo plus fulvestrant for patients with HR+/HER2- advanced breast cancer after progressing on endocrine therapy: Updated analysis of the phase III study [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2024; 2024 Dec 10-13; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(12 Suppl):Abstract nr PS2-02.
No takes yet. Share an insight, caveat, or question.
Tao et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: